BACKGROUND: We tested the oral mammalian target of rapamycin (mTOR) inhibitor everolimus in addition to paclitaxel in patients with HER2-negative tumours not responding to initial neoadjuvant cytotoxic and anti-angiogenic treatment. METHODS:Patients with primary HER2-negative tumours received four neoadjuvant cycles of epirubicin/cyclophosphamide (EC) with or without bevacizumab. Patients without clinical response were randomised to receive weekly paclitaxel (80 mg/m(2)) with or without everolimus (5mg p.o. daily, after a step-wise dose-escalation starting from 2.5mg bid) for 12 weeks before surgery. To detect an increase in pathological complete response (pCR; ypT0 ypN0) from 5% to 12.1% (odds ratio 2.62) 566 patients had to be recruited. The trial was stopped prematurely due to completion of accrual in the main study. FINDINGS: Of 1948 patients initially starting neoadjuvant treatment 403 were randomised. A total of 18 (4.6%) patients, 7 (3.6%) treated with paclitaxel and everolimus and 11 (5.6%) treated with paclitaxel alone had a pCR (odds ratio 0.36 (OR) (95% confidence interval (CI), 0.24-1.6) p=0.34). Overall response rate in breast and lymph nodes at surgery was 52.2% after paclitaxel plus everolimus and 61.7% after paclitaxel alone (p=0.063). Breast conserving treatment was performed in 54.4% of patients with the combination treatment and 61.9% with paclitaxel alone (p=0.20). Mucosal inflammation, thrombocytopenia, neutropenia, infection, and skin rash were more frequent when everolimus was added to paclitaxel. INTERPRETATION: Neoadjuvant therapy with everolimus and paclitaxel for patients with HER2-negative disease unresponsive to EC with or withoutbevacizumab did not improve the pCR rate. Long-term outcome is awaited. FUNDING: Novartis, Roche, and Sanofi-Aventis.
RCT Entities:
BACKGROUND: We tested the oral mammalian target of rapamycin (mTOR) inhibitor everolimus in addition to paclitaxel in patients with HER2-negative tumours not responding to initial neoadjuvant cytotoxic and anti-angiogenic treatment. METHODS:Patients with primary HER2-negative tumours received four neoadjuvant cycles of epirubicin/cyclophosphamide (EC) with or without bevacizumab. Patients without clinical response were randomised to receive weekly paclitaxel (80 mg/m(2)) with or without everolimus (5mg p.o. daily, after a step-wise dose-escalation starting from 2.5mg bid) for 12 weeks before surgery. To detect an increase in pathological complete response (pCR; ypT0 ypN0) from 5% to 12.1% (odds ratio 2.62) 566 patients had to be recruited. The trial was stopped prematurely due to completion of accrual in the main study. FINDINGS: Of 1948 patients initially starting neoadjuvant treatment 403 were randomised. A total of 18 (4.6%) patients, 7 (3.6%) treated with paclitaxel and everolimus and 11 (5.6%) treated with paclitaxel alone had a pCR (odds ratio 0.36 (OR) (95% confidence interval (CI), 0.24-1.6) p=0.34). Overall response rate in breast and lymph nodes at surgery was 52.2% after paclitaxel plus everolimus and 61.7% after paclitaxel alone (p=0.063). Breast conserving treatment was performed in 54.4% of patients with the combination treatment and 61.9% with paclitaxel alone (p=0.20). Mucosal inflammation, thrombocytopenia, neutropenia, infection, and skin rash were more frequent when everolimus was added to paclitaxel. INTERPRETATION: Neoadjuvant therapy with everolimus and paclitaxel for patients with HER2-negative disease unresponsive to EC with or without bevacizumab did not improve the pCR rate. Long-term outcome is awaited. FUNDING: Novartis, Roche, and Sanofi-Aventis.
Authors: Berit M Pfitzner; Bianca Lederer; Judith Lindner; Christine Solbach; Knut Engels; Mahdi Rezai; Karel Dohnal; Hans Tesch; Martin L Hansmann; Christoph Salat; Michaela Beer; Andreas Schneeweiss; Peter Sinn; Agnes Bankfalvi; Silvia Darb-Esfahani; Gunter von Minckwitz; Bruno V Sinn; Ralf Kronenwett; Karsten Weber; Carsten Denkert; Sibylle Loibl Journal: Mod Pathol Date: 2017-12-22 Impact factor: 7.842
Authors: A M Gonzalez-Angulo; A Akcakanat; S Liu; M C Green; J L Murray; H Chen; S L Palla; K B Koenig; A M Brewster; V Valero; N K Ibrahim; S Moulder-Thompson; J K Litton; E Tarco; J Moore; P Flores; D Crawford; M J Dryden; W F Symmans; A Sahin; S H Giordano; L Pusztai; K-A Do; G B Mills; G N Hortobagyi; F Meric-Bernstam Journal: Ann Oncol Date: 2014-03-24 Impact factor: 32.976
Authors: Peter A Fasching; Sibylle Loibl; Chunling Hu; Steven N Hart; Hermela Shimelis; Raymond Moore; Christian Schem; Hans Tesch; Michael Untch; Jörn Hilfrich; Mahdi Rezai; Bernd Gerber; Serban Dan Costa; Jens-Uwe Blohmer; Tanja Fehm; Jens Huober; Cornelia Liedtke; Richard M Weinshilboum; Liewei Wang; James N Ingle; Volkmar Müller; Valentina Nekljudova; Karsten E Weber; Brigitte Rack; Matthias Rübner; Gunter von Minckwitz; Fergus J Couch Journal: J Clin Oncol Date: 2018-05-23 Impact factor: 44.544
Authors: Larissa A Korde; Mark R Somerfield; Lisa A Carey; Jennie R Crews; Neelima Denduluri; E Shelley Hwang; Seema A Khan; Sibylle Loibl; Elizabeth A Morris; Alejandra Perez; Meredith M Regan; Patricia A Spears; Preeti K Sudheendra; W Fraser Symmans; Rachel L Yung; Brittany E Harvey; Dawn L Hershman Journal: J Clin Oncol Date: 2021-01-28 Impact factor: 44.544